Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA.
Location: United States
Total raised: $250M
Investors 1
| Date | Name | Website |
| 16.09.2024 | ARCH Ventu... | archventur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.01.2026 | Series B | $250M | Venrock |
Mentions in press and media 6
| Date | Title | Description |
| 14.01.2026 | Mirador Therapeutics Secures $250M, Accelerates Precision Medicine | Mirador Therapeutics secured $250M in Series B funding. This propels their innovative precision medicine strategy. Total capital raised now exceeds $650M. The San Diego firm targets immune-mediated inflammatory and fibrotic diseases. Funds ... |
| 13.01.2026 | Mirador Raises $250M in Series B Funding | Mirador Therapeutics, a San Diego, CA-based clinical-stage precision medicine company developing new therapies for immune-mediated inflammatory and fibrotic diseases, raised $250M in Series B funding. Backers included T. Rowe Price Investme... |
| 12.01.2026 | Mirador Therapeutics: $250 Million Series B Raised And Multi-Asset Immuno-Fibrotic Pipeline Advanced | Mirador Therapeutics announced it is advancing multiple clinical-stage programs across Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and idiopathic pulmonary fibrosis, with more than 10 clinical readouts expected by the end of ... |
| 28.09.2024 | ARCH Venture Partners: $3+ Billion New Fund Raised To Invest In Next-Gen Biotech Companies | ARCH Venture Partners announced the closing of ARCH Venture Fund XIII, a venture capital fund with over $3 billion to support the founding and growth of early-stage biotechnology companies. ARCH invests in early-stage companies that prevent... |
| 25.03.2024 | Mirador Therapeutics Raises Over 400M in Funding | Mirador Therapeutics, Inc., a San Diego, CA-based company advancing multiple therapeutic programs, raised $400m in financing. The round was led by led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount. Other premie... |
| - | Mirador Therapeutics | “Mirador – Redefining Immunology & Inflammation with Precision” |